FuturHealth now offers Apple Fitness+ at no cost for GLP-1 weight loss members, providing access to thousands of workouts and meditations to support sustainable results.

Novo Nordisk lowers 2025 outlook despite strong GLP-1 sales growth. What shifting obesity drug trends mean for the fitness industry.

Hims & Hers closed Q2 2025 with $544.8M in revenue up 73% year-over-year net income of $42.5M, and 2.44M subscribers. The company reaffirmed its full-year outlook.

One in three Canadian adults are now classified as obese, according to new data from the Canadian Medical Association Journal. The study reveals a post-pandemic acceleration in obesity rates, raising important considerations for the fitness industry as it adapts to shifting public health trends and the rise of GLP-1 use.

Hims & Hers enters Canadian market with a digital weight loss program leveraging generic semaglutide, signaling increased competition and accessibility in the growing GLP-1 and obesity treatment sector.

WeightWatchers expands its partnership with Novo Nordisk to improve access to FDA-approved Wegovy for weight loss. The collaboration includes a limited-time price of $299, integrated pharmacy fulfillment, and a commitment to real-world research combining GLP-1 treatment with lifestyle support.

ISSA launches a GLP-1 Weight Loss Support Training course to help fitness professionals safely guide clients using medications like Ozempic and Wegovy, addressing physical, emotional, and behavioral changes.

A new claims analysis by Aon found that GLP-1 users experienced a 44 percent reduction in cardiac hospitalizations and slower medical cost growth compared to matched control groups.

The UK health and fitness market has hit a new high, generating £5.7bn in annual revenue and reaching 11.5 million members across 5,607 clubs. A new industry report from ukactive, with analysis from Deloitte, highlights strong sector growth, rising gym usage, and major investment potential—even amid economic headwinds.

New research reveals UK-based fitness chain The Gym Group has generated $2.25 billion USD in social value since 2016—improving health, education outcomes, and reducing crime. It’s the first private operator to measure its impact using Sport England’s Social Value Calculator.

The NHS is urging clinicians to integrate physical activity into routine care, citing its role in preventing and managing chronic conditions—and the billions it could save the healthcare system.

Life Time has launched its LTH supplement line on Amazon, making more than 50 research-backed products accessible to a wider audience. The move comes as 71% of U.S. adults report confusion around supplement choices.

Garmin’s fēnix smartwatches are supporting spaceflight research on the Fram2 mission, collecting biometric data in orbit. Here’s what it means for the future of wearables in fitness and health monitoring.

Noom has partnered with LillyDirect® pharmacy provider Gifthealth to streamline access to Zepbound® vials for weight management, enhancing its GLP-1 Companion program for eligible users.

GymNation is turning heads with its latest concept — an in-gym hotel promising recovery without the commute. Dumbbell-shaped towels, protein-on-demand, and "Gymflix" are just the beginning. Is this the future of fitness, or something a little more tongue-in-cheek?

Novo Nordisk says unauthorized compounded versions of Wegovy are cutting into U.S. sales and warns it may pursue legal action to protect its intellectual property. The company has also expanded access to its official savings program.

Discover how F45 Training and Dr. B are addressing the rising demand for GLP-1 medications by combining fitness, nutrition, and telehealth solutions to support sustainable weight management.

Biden Administration proposes expanding Medicare and Medicaid to cover GLP-1 medications, addressing obesity and opening new opportunities for the fitness industry. Learn how this could reshape access to care and gym engagement.

Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

Discover the unexpected U.S. state leading the surge in GLP-1 weight loss drug usage, driven by celebrity endorsements and healthcare innovations, with significant economic implications.